Merestinib

Phase 1Terminated

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bone Metastases

Conditions

Bone Metastases, Breast Cancer

Trial Timeline

Jan 11, 2018 → Jun 24, 2019

NCT ID

NCT03292536

About Merestinib

Merestinib is a phase 1 stage product being developed by Eli Lilly for Bone Metastases. The current trial status is terminated. This product is registered under clinical trial identifier NCT03292536. Target conditions include Bone Metastases, Breast Cancer.

What happened to similar drugs?

10 of 20 similar drugs in Bone Metastases were approved

Approved (10) Terminated (1) Active (9)

🔄Denosumab + Zoledronic AcidDaiichi SankyoPhase 3

🔄Arzoxifene + PlaceboEli LillyPhase 3

🔄TanezumabEli LillyPhase 3

🔄Anastrozole + TamoxifenAstraZenecaPhase 3

🔄zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplementsNovartisPhase 3

🔄Zoledronic acidNovartisPhase 3

🔄Zoledronic acid + LetrozoleNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03292536	Phase 1	Terminated	Jan 11, 2018	Jun 24, 2019	Bone Metastases
NCT02920996	Phase 2	Terminated	Nov 11, 2016	Oct 1, 2023	Carcinoma, Non-Small-Cell Lung
NCT02779738	Phase 1	Completed	May 1, 2016	Aug 1, 2016	Healthy

Competing Products

20 competing products in Bone Metastases

See all competitors

Product	Company	Stage	Hype Score
Denosumab + Zoledronic Acid	Daiichi Sankyo	Phase 3	40
Enzalutamide	Astellas Pharma	Phase 2	35
Enzalutamide	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
FORTEO + Placebo	Eli Lilly	Phase 1	29
Arzoxifene + Placebo	Eli Lilly	Phase 3	40
Tanezumab	Eli Lilly	Phase 3	40
Anastrozole + Tamoxifen	AstraZeneca	Phase 3	40
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Zoledronic acid + Letrozole	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Nilotinib	Novartis	Phase 1	29
Reclast (ZOL446, zoledronic acid)	Novartis	Approved	43
Zoledronic acid	Novartis	Phase 3	32
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid	Novartis	Phase 3	40
zoledronic acid	Novartis	Phase 1	29
Ruxolitinib continuous therapy	Novartis	Phase 2	39
zoledronic acid	Novartis	Approved	43